| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 04/21/2011 | US20110091542 Baclofen and r-baclofen gastroretentive drug delivery systems |
| 04/21/2011 | US20110091541 Preparation of formulations of angiotensin II at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 04/21/2011 | US20110091540 Polymeric compositions and their method of use in combination with active agents |
| 04/21/2011 | US20110091539 Micronized Tanaproget and Compositions Containing Same |
| 04/21/2011 | US20110091538 Polymer adapted to release bioactive agents in vivo, pharmaceutical composition and method of preparation thereof |
| 04/21/2011 | US20110091537 Anti-misuse solid oral pharmaceutical form provided with a specific modified release profile |
| 04/21/2011 | US20110091536 Compositions comprising euphorbia prostrata and process of preparation thereof |
| 04/21/2011 | US20110091535 Solid pharmaceutical formulation |
| 04/21/2011 | US20110091534 Compositions comprising polymeric micelles for drug delivery |
| 04/21/2011 | US20110091533 Amphiphilic polymer capsules and related methods of interfacial assembly |
| 04/21/2011 | US20110091532 Composition for the treatment of arthritis containing a dibenzo-p-dioxin derivative as the active ingredient |
| 04/21/2011 | US20110091531 Cooling Composition |
| 04/21/2011 | US20110091530 Oligopeptide tyrosinase inhibitors and uses thereof |
| 04/21/2011 | US20110091529 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| 04/21/2011 | US20110091528 Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| 04/21/2011 | US20110091527 Compositions and methods for reducing scar formation in wound healing |
| 04/21/2011 | US20110091526 Parasite Vaccine |
| 04/21/2011 | US20110091525 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 04/21/2011 | US20110091524 Biomarkers for sensitivity to anti-igf1r therapy |
| 04/21/2011 | US20110091523 Cochleate compositions directed against expression of proteins |
| 04/21/2011 | US20110091522 Edible chew pill jacket |
| 04/21/2011 | US20110091521 Edible spoon for dissociating into consumable predetermined clumps in order to prevent dissociating into random granules that would make consumption more difficult |
| 04/21/2011 | US20110091520 Sustained Release Intraocular Implants and Methods for Treating Ocular Neuropathies |
| 04/21/2011 | US20110091519 Controlling resorption of bioresorbable medical implant material |
| 04/21/2011 | US20110091516 Muscle-based grafts/implants |
| 04/21/2011 | US20110091515 Drug-eluting medical devices |
| 04/21/2011 | US20110091513 Water-dispersible and multicomponent fibers from sulfopolyesters |
| 04/21/2011 | US20110091512 Highly porous, large polymeric particles and methods of preparation and use |
| 04/21/2011 | US20110091511 Transdermal delivery of drugs based on crystal size |
| 04/21/2011 | US20110091510 Nanorod materials and methods of making and using same |
| 04/21/2011 | US20110091509 Benzonatate compositions and methods of use |
| 04/21/2011 | US20110091508 Oligofluorinated cross-linked polymers and uses thereof |
| 04/21/2011 | US20110091488 Water-swellable polymers |
| 04/21/2011 | US20110091415 Hydroxyethyl Starch-Containing Polypeptide Compositions |
| 04/21/2011 | US20110091406 Composition and method for protecting labile active components during high temperature drying |
| 04/21/2011 | US20110091392 Compositions for the treatment and prevention of infections of the oral cavity |
| 04/21/2011 | US20110091391 Discrete tunable sensing elements and compositions for measuring and reporting status and/or product performance |
| 04/21/2011 | US20110091379 Method for treating tumors and their metastases |
| 04/21/2011 | DE112008003727T5 Nanopartikel-Träger für Wirkstoffverabreichung und Verfahren für ihre Herstellung Nanoparticle carriers for drug delivery and methods for their preparation |
| 04/21/2011 | DE102010046464A1 Transdermal system, useful for indicating breast cancer in postmenopausal women, comprises aromatase inhibitor, drug-impermeable skin protective layer, reservoir, optional drug-permeable membrane and a carrier for reservoir or membrane |
| 04/21/2011 | CA2814237A1 Water soluble drug-solubilizer powders and their uses |
| 04/21/2011 | CA2777856A1 Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof |
| 04/21/2011 | CA2777676A1 Method and apparatus for manufacturing adhesive patch |
| 04/21/2011 | CA2777537A1 Compositions and methods for mild sedation, anxiolysis and analgesia in the procedural setting |
| 04/21/2011 | CA2777517A1 Adhesive patch |
| 04/21/2011 | CA2777400A1 Granulysin in immunotherapy |
| 04/21/2011 | CA2777367A1 Reducing the risk of pathological effects of traumatic brain injury |
| 04/21/2011 | CA2777010A1 Anti-misuse solid oral dosage form provided having a modified specific release profile |
| 04/21/2011 | CA2776845A1 Aerosol formulations comprising a wetting agent to reduce particle deposition |
| 04/21/2011 | CA2776796A1 Porphyrin nanovesicles |
| 04/21/2011 | CA2776359A1 Improved medicinal aerosol formulations |
| 04/20/2011 | EP2311956A1 Methods for making APO-2 ligand using divalent metal ions |
| 04/20/2011 | EP2311895A1 Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups |
| 04/20/2011 | EP2311885A1 Production of carrageenan and carrageenan products |
| 04/20/2011 | EP2311871A2 IL-1 antagonist stable liquid formulation |
| 04/20/2011 | EP2311793A1 Crystalline levosalbutamol sulphate (Form II) |
| 04/20/2011 | EP2311498A1 External preparation comprising fatty acid salt or benzoic acid salt of basic pharmacologically active component, and method for production thereof |
| 04/20/2011 | EP2311497A1 Use of oligouronates |
| 04/20/2011 | EP2311496A1 A combination of morphine and oxycodone for use in the alleviation or prevention of pain |
| 04/20/2011 | EP2311492A1 Antibody-containing stabilized preparations |
| 04/20/2011 | EP2311489A2 Formulation of antibody-containing solutions comprising a sugar as a stabilizer |
| 04/20/2011 | EP2311466A2 Antimicrobial compounds and methods for their use |
| 04/20/2011 | EP2311465A1 Remedies for diseases to be applied to eye |
| 04/20/2011 | EP2311460A1 Oxymorphone controlled release formulations |
| 04/20/2011 | EP2311459A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 04/20/2011 | EP2311458A1 Tamper resistant dosage forms |
| 04/20/2011 | EP2311452A1 Topical composition comprising n-acetyl glucosamine |
| 04/20/2011 | EP2311444A1 Method for preparing a stabilised menthol emulsion |
| 04/20/2011 | EP2311442A1 Multiparticulate modified release composition |
| 04/20/2011 | EP2311441A1 Dosage formulations for acetylcholinesterase inhibitors |
| 04/20/2011 | EP2311440A1 Controlled delivery of tetracycline compounds and tetracycline derivatives |
| 04/20/2011 | EP2311439A1 Galenical formulations of aliskiren and hydrochlorothiazide |
| 04/20/2011 | EP2311438A1 Matrix for sustained, invariant and independent release of active compounds |
| 04/20/2011 | EP2311437A1 Stabilised compositions of factor VII polypeptides |
| 04/20/2011 | EP2311436A1 Stabilized protein crystals, formulations containing them and methods of making them |
| 04/20/2011 | EP2311435A1 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
| 04/20/2011 | EP2311434A1 Dry powder inhaler formulations comprising surface-modified particles with anti-adherent additives |
| 04/20/2011 | EP2311433A2 Method for treating intraocular neovascular diseases |
| 04/20/2011 | EP2311432A1 Prevention and reduction of blood loss |
| 04/20/2011 | EP2311431A1 Short duration depot formulations |
| 04/20/2011 | EP2311404A1 Injectable and swellable microspheres for dermal augmentation |
| 04/20/2011 | EP2310459A2 Improved cross-linked compositions |
| 04/20/2011 | EP2310440A2 Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| 04/20/2011 | EP2310120A1 Capsule with organic/inorganic hybrid wall |
| 04/20/2011 | EP2310062A1 Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness |
| 04/20/2011 | EP2310053A1 Pharmaceutical compositions comprising a complex of aminocyclohexane derivatives and cyclodextrin |
| 04/20/2011 | EP2310052A2 Acne treatment compositions comprising nanosilver and uses |
| 04/20/2011 | EP2310022A1 Topical medicament |
| 04/20/2011 | EP2310018A1 Use of nifurtimox for treating giardiasis |
| 04/20/2011 | EP2310009A2 Parenteral and oral formulations of benzimidazoles |
| 04/20/2011 | EP2310008A2 Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders |
| 04/20/2011 | EP2310002A1 Protective gel based on chitosan and oxidized polysaccharide |
| 04/20/2011 | EP2310001A2 Transdermal estrogen device and delivery |
| 04/20/2011 | EP2310000A1 Dermal delivery |
| 04/20/2011 | EP2309999A1 Coated particles containing pharmaceutically active agents |
| 04/20/2011 | EP2309998A1 Effervescent tablets/granules |
| 04/20/2011 | EP2309997A2 Composition and method of preparation of release systems for constant (zero-order) release of active agents |
| 04/20/2011 | EP2309996A2 Amorphous ambrisentan |
| 04/20/2011 | EP2309995A1 Pharmaceutical formulation for lowering pulmonary blood pressure |
| 04/20/2011 | EP2309994A2 Sustained release pharmaceutical compositions comprising quetiapine |